Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia

NCT04657094 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04657094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04657094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Acalabrutinib for the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 16, 2021
Completion date
February 8, 2027
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, warm antibody autoimmune hemolytic anemia